| scholarly article | Q13442814 |
| P50 | author | Alexandros Makriyannis | Q28480394 |
| P2093 | author name string | Steven R Goldberg | |
| Bernard Le Foll | |||
| Islam Gamaleddin | |||
| Maria Scherma | |||
| Mihail Guranda | |||
| Subramanian K Vadivel | |||
| Walter Fratta | |||
| P2860 | cites work | Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha | Q24319974 |
| Role of endogenous cannabinoids in synaptic signaling | Q28185075 | ||
| Identification of a high-affinity binding site involved in the transport of endocannabinoids | Q28284073 | ||
| Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors | Q28582567 | ||
| Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 | ||
| The anandamide transport inhibitor AM404 activates vanilloid receptors. | Q31384563 | ||
| Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments | Q33695248 | ||
| Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity | Q33921608 | ||
| The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors | Q33940288 | ||
| The endocannabinoid system: a physiological perspective on its role in psychomotor control | Q34099000 | ||
| Functional role of high-affinity anandamide transport, as revealed by selective inhibition | Q34436019 | ||
| Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction | Q34661063 | ||
| Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors | Q35202878 | ||
| The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake | Q35593066 | ||
| Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. | Q35938826 | ||
| The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats | Q36176513 | ||
| Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats | Q37146387 | ||
| Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies | Q37164812 | ||
| Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression | Q37414566 | ||
| Neuropsychiatric adverse effects of centrally acting antiobesity drugs. | Q37939362 | ||
| Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase | Q40658993 | ||
| Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats | Q42661076 | ||
| The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. | Q43227468 | ||
| The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase | Q43512138 | ||
| A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid | Q43893543 | ||
| Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. | Q43986557 | ||
| SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats | Q44190296 | ||
| Nicotine maintains robust self-administration in rats on a limited-access schedule | Q44290531 | ||
| Novel selective and metabolically stable inhibitors of anandamide cellular uptake | Q44430771 | ||
| Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. | Q44925249 | ||
| Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. | Q45108517 | ||
| Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. | Q45173372 | ||
| Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. | Q45988694 | ||
| Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats | Q46471752 | ||
| Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine | Q46673452 | ||
| Anxiolytic-like properties of the anandamide transport inhibitor AM404. | Q46689323 | ||
| Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. | Q46765854 | ||
| The anandamide transport inhibitor AM404 reduces ethanol self-administration. | Q51980223 | ||
| Heroin self-administration in rats under a progressive ratio schedule of reinforcement. | Q52228717 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nicotine | Q12144 |
| P304 | page(s) | 564-571 | |
| P577 | publication date | 2013-02-20 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking | |
| P478 | volume | 27 |
| Q47225379 | Acute and chronic modulation of striatal endocannabinoid-mediated plasticity by nicotine |
| Q38793610 | Cannabinoid CB2 Receptor Mediates Nicotine-Induced Anti-Inflammation in N9 Microglial Cells Exposed to β Amyloid via Protein Kinase C. |
| Q39787140 | Dissociating the role of endocannabinoids in the pleasurable and motivational properties of social play behaviour in rats |
| Q30373359 | Endocannabinoid signalling in reward and addiction. |
| Q38686274 | Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives |
| Q90603824 | More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder |
| Q38338793 | Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation Medications |
| Q91991315 | Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse |
| Q30244252 | Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research |
| Q46111417 | Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation |
| Q90248156 | Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders |
| Q26825476 | Role of cues and contexts on drug-seeking behaviour |
| Q35216481 | Role of the endogenous cannabinoid system in nicotine addiction: novel insights |
| Q36839896 | Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys |
Search more.